Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
July 17, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...
Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Program
July 15, 2019 11:00 ET
|
Seelos Therapeutics, Inc.
Team Sanfilippo Foundation to Provide Funding for Planned FDA/EMA Open-Label Phase IIb/III and Expanded Access Study in Sanfilippo Syndrome Initial Patient Dosing is Scheduled to Begin in Q3 2019 ...
Seelos Therapeutics Receives Notice of Allowance for a US Patent for SLS-005 in New Indication of Friedreich Ataxia
July 02, 2019 11:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they have received a Notice of Allowance from...
Seelos Therapeutics Added to Russell Microcap® Index
July 01, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has been added to the Russell Microcap®...
Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University
June 27, 2019 07:00 ET
|
Seelos Therapeutics, Inc.
Validated, Pre-Clinical Success Shown in Modifying the Regulation of the SNCA Gene Which Encodes Alpha-Synuclein Expression Program Continues to Expand Seelos’ Alpha-Synuclein Targeted Parkinson’s...
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
June 06, 2019 07:00 ET
|
Seelos Therapeutics, Inc.
─ Scheduled to Meet with FDA to Design Proof-of-Concept Study in Suicidality-PTSD ─ Appoints Warren W. Wasiewski, MD as Chief Scientific Officer ─ Seelos to Webcast Presentation at the Jefferies...
Seelos Therapeutics Reports Q1 2019 Pipeline Update
May 21, 2019 08:30 ET
|
Seelos Therapeutics, Inc.
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an FDA/EMA open-label phase IIb/III trial in Q3 2019 – - Continuing progress to initiate phase I study with...
Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC
April 16, 2019 08:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will present and host 1x1 and small group...
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
March 28, 2019 17:00 ET
|
Seelos Therapeutics, Inc.
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 – - Plan to initiate phase I study with intranasal racemic ketamine in...
Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA
March 07, 2019 08:00 ET
|
Seelos Therapeutics, Inc.
Well-Validated, Pre-Clinical Success Shown in the Reduction of Alpha-Synuclein New Compound Expands Seelos’ Parkinson's Portfolio NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics,...